Limits...
Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit.

Gharbi M, Moore LS, Gilchrist M, Thomas CP, Bamford K, Brannigan ET, Holmes AH - Int. J. Antimicrob. Agents (2015)

Bottom Line: Analysis of alternative antimicrobials showed a significant increase in amikacin consumption post-intervention from 0.54 to 3.41 DDD/100OBD/year (slope +0.72, 95% CI 0.29-1.15; P=0.01).Total antimicrobials significantly decreased from 176.21 to 126.24 DDD/100OBD/year (P=0.05).Further validation using real-time data is needed.

View Article: PubMed Central - PubMed

Affiliation: The National Centre for Infection Prevention and Management, Imperial College London, Du Cane Road, London W12 ONN, UK. Electronic address: m.gharbi@imperial.ac.uk.

No MeSH data available.


Related in: MedlinePlus

Change rate of the consumption of antimicrobials active against Gram-negative bacteria (in DDD/100 OBD) between 2008–2009 and 2013–2014 in a West London renal cohort. DDD, defined daily doses; OBD, occupied bed-days.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4526541&req=5

fig0020: Change rate of the consumption of antimicrobials active against Gram-negative bacteria (in DDD/100 OBD) between 2008–2009 and 2013–2014 in a West London renal cohort. DDD, defined daily doses; OBD, occupied bed-days.

Mentions: Consumption of alternative antimicrobials post-intervention is described Table 1 and Fig. 4. In the post-intervention phase, the two alternative Gram-negative antimicrobial classes showed a significant increase in consumption from 2008–2009 to 2013–2014; amikacin increased from 0.54 to 3.41 DDD/100 OBD/year (slope = +0.72, 95% CI 0.29–1.15; P = 0.01) and cephalosporins from 0.98 to 1.88 DDD/100 OBD/year (slope = +0.19, 95% CI 0.12–0.27; P < 0.01). Use of ertapenem and imipenem demonstrated a non-significant increase over the post-intervention period, although usage of the latter was in general particularly low. The commonly encountered inhibitor/penicillin combinations, i.e. amoxicillin/clavulanic acid and piperacillin/tazobactam (TZP), did not change significantly over time (respectively, slope = −0.09, 95% CI −1.31 to 1.12, P = 0.85; and slope = +0.65, 95% CI −0.96 to 2.27, P = 0.33). Quinolones significantly decreased from 24.82 to 18.57 DDD/100 OBD/year (slope = −1.42, 95% CI −2.05 to −0.78; P < 0.01). The overall amount of antimicrobials consumed significantly decreased from 176.21 to 126.24 DDD/100 OBD/year (slope = −7.21, 95% CI −14.85 to −0.01; P = 0.05).


Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit.

Gharbi M, Moore LS, Gilchrist M, Thomas CP, Bamford K, Brannigan ET, Holmes AH - Int. J. Antimicrob. Agents (2015)

Change rate of the consumption of antimicrobials active against Gram-negative bacteria (in DDD/100 OBD) between 2008–2009 and 2013–2014 in a West London renal cohort. DDD, defined daily doses; OBD, occupied bed-days.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4526541&req=5

fig0020: Change rate of the consumption of antimicrobials active against Gram-negative bacteria (in DDD/100 OBD) between 2008–2009 and 2013–2014 in a West London renal cohort. DDD, defined daily doses; OBD, occupied bed-days.
Mentions: Consumption of alternative antimicrobials post-intervention is described Table 1 and Fig. 4. In the post-intervention phase, the two alternative Gram-negative antimicrobial classes showed a significant increase in consumption from 2008–2009 to 2013–2014; amikacin increased from 0.54 to 3.41 DDD/100 OBD/year (slope = +0.72, 95% CI 0.29–1.15; P = 0.01) and cephalosporins from 0.98 to 1.88 DDD/100 OBD/year (slope = +0.19, 95% CI 0.12–0.27; P < 0.01). Use of ertapenem and imipenem demonstrated a non-significant increase over the post-intervention period, although usage of the latter was in general particularly low. The commonly encountered inhibitor/penicillin combinations, i.e. amoxicillin/clavulanic acid and piperacillin/tazobactam (TZP), did not change significantly over time (respectively, slope = −0.09, 95% CI −1.31 to 1.12, P = 0.85; and slope = +0.65, 95% CI −0.96 to 2.27, P = 0.33). Quinolones significantly decreased from 24.82 to 18.57 DDD/100 OBD/year (slope = −1.42, 95% CI −2.05 to −0.78; P < 0.01). The overall amount of antimicrobials consumed significantly decreased from 176.21 to 126.24 DDD/100 OBD/year (slope = −7.21, 95% CI −14.85 to −0.01; P = 0.05).

Bottom Line: Analysis of alternative antimicrobials showed a significant increase in amikacin consumption post-intervention from 0.54 to 3.41 DDD/100OBD/year (slope +0.72, 95% CI 0.29-1.15; P=0.01).Total antimicrobials significantly decreased from 176.21 to 126.24 DDD/100OBD/year (P=0.05).Further validation using real-time data is needed.

View Article: PubMed Central - PubMed

Affiliation: The National Centre for Infection Prevention and Management, Imperial College London, Du Cane Road, London W12 ONN, UK. Electronic address: m.gharbi@imperial.ac.uk.

No MeSH data available.


Related in: MedlinePlus